| pubmed-article:7926375 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7926375 | lifeskim:mentions | umls-concept:C0021368 | lld:lifeskim |
| pubmed-article:7926375 | lifeskim:mentions | umls-concept:C0600251 | lld:lifeskim |
| pubmed-article:7926375 | lifeskim:mentions | umls-concept:C1707929 | lld:lifeskim |
| pubmed-article:7926375 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:7926375 | lifeskim:mentions | umls-concept:C0070750 | lld:lifeskim |
| pubmed-article:7926375 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:7926375 | pubmed:dateCreated | 1994-11-16 | lld:pubmed |
| pubmed-article:7926375 | pubmed:abstractText | The topical application of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) to murine skin produces acute inflammatory and hyperplastic responses that have been associated with the promotion stage of skin carcinogenesis. It has been shown in a previous study that TPA induces the expression of the highly inflammatory cytokine, interleukin (IL) -1 alpha, in the epidermis of SENCAR mice. The goal of this study was to investigate the role of IL-1 alpha in several TPA-induced responses in skin. Topical application of TPA (1 microgram) enhanced the production of immunoreactive IL-1 alpha protein, primarily associated with the suprabasal keratinocytes. IL-1 alpha intradermally injected in the dorsal surface significantly increased (P < 0.001) vascular permeability at low concentrations (1-1000 microU) and increased (P < 0.001) inflammatory cell infiltration and epidermal hyperplasia at higher concentrations (10(3) U). TPA produced fourfold increases in vascular permeability as measured by Evans blue dye leakage; this effect was prevented by intradermal injection of anti-IL-1 alpha antibody (25-75 micrograms). Furthermore, injected anti-IL-1 alpha antibody significantly reduced (P < 0.001) TPA-induced inflammatory cell infiltration and epidermal hyperplasia. This study suggests that IL-1 alpha directly or indirectly mediates the inflammatory and hyperplastic responses elicited by topical treatment with TPA. | lld:pubmed |
| pubmed-article:7926375 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7926375 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7926375 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7926375 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7926375 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7926375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7926375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7926375 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7926375 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7926375 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:7926375 | pubmed:issn | 0892-6638 | lld:pubmed |
| pubmed-article:7926375 | pubmed:author | pubmed-author:LeeW YWY | lld:pubmed |
| pubmed-article:7926375 | pubmed:author | pubmed-author:FischerS MSM | lld:pubmed |
| pubmed-article:7926375 | pubmed:author | pubmed-author:LockniskarM... | lld:pubmed |
| pubmed-article:7926375 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7926375 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:7926375 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7926375 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7926375 | pubmed:pagination | 1081-7 | lld:pubmed |
| pubmed-article:7926375 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:meshHeading | pubmed-meshheading:7926375-... | lld:pubmed |
| pubmed-article:7926375 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7926375 | pubmed:articleTitle | Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. | lld:pubmed |
| pubmed-article:7926375 | pubmed:affiliation | Division of Pharmacology/Toxicology, College of Pharmacy, University of Texas at Austin 78712. | lld:pubmed |
| pubmed-article:7926375 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7926375 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7926375 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7926375 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7926375 | lld:pubmed |
